GlassScriptPhysician profile
Catherine Nancy Geiger
NPI 1518651363
$7,095.40
in general payments reported to CMS, 2019-2025
35 companies · $3,262 in 2025
The $3,262 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $775 · 2024: $3,058 · 2025: $3,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,886 · Consulting Fee: $150 · Education: $59.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,885.60 |
| Consulting Fee | $150.00 |
| Education | $59.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,236.97 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $677.23 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $656.49 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $602.77 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $540.79 | 2023-2025 | |
| United Therapeutics Corporation | $518.63 | 2023-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.45 | 2023-2025 | Ofev, Jascayd, Stiolto Respimat |
| Amgen INC. | $238.59 | 2023-2025 | Tezspire |
| Insmed, INC. | $217.75 | 2024-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $164.71 | 2023-2025 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $160.82 | 2024-2025 | Lumryz |
| Merck Sharp & Dohme LLC | $148.86 | 2024 | Zerbaxa, Keytruda, Recarbrio |
| Ani Pharmaceuticals, INC. | $143.55 | 2024-2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $128.82 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $127.62 | 2023-2024 | Yupelri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $124.20 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Baxter Healthcare | $118.16 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Harmony Biosciences LLC | $114.18 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $102.99 | 2024 | Opsumit, Uptravi |
| Electromed, INC. | $99.40 | 2024-2025 | Smartvest |
| Viatris Specialty LLC | $92.59 | 2025 | Yupelri |
| Verona Pharma, INC. | $80.43 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Vifor Pharma, INC. | $56.13 | 2024 | Zemaira |
| Genentech USA, INC. | $51.64 | 2023-2025 | Xolair |
| Pfizer INC. | $44.66 | 2024 | |
| Lilly USA, LLC | $34.97 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $32.73 | 2025 | |
| Philips North America LLC | $30.23 | 2024 | (Ak6) Vest Therapy |
| Mallinckrodt Hospital Products INC. | $25.07 | 2023 | Acthar |
| Stryker Corporation | $24.92 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Tactile Systems Technology INC | $23.88 | 2025 | Flexitouch Plus, Nimbl |
| Inogen, INC. | $16.57 | 2025 | |
| Almatica Pharma LLC | $15.82 | 2023 | Loreev Xr |
| Paratek Pharmaceuticals, INC. | $13.98 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Geiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.